CBD Oil for Bipolar Disorder: What the Research Says and What to Know Before You Try It | PureCraft CBD
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Bipolar disorder is a serious, complex psychiatric condition that requires professional management. CBD is not a mood stabilizer and cannot replace lithium, valproate, lamotrigine, or other prescribed medications for bipolar disorder. Stopping or reducing bipolar medications without medical supervision can be dangerous and potentially life-threatening. Always consult your psychiatrist or prescribing physician before adding any supplement, including CBD, to your treatment plan. If you or someone you know is experiencing a manic episode or psychiatric crisis, seek emergency care immediately.
Bipolar disorder is one of the most complex conditions in psychiatry — a cycling illness that swings between states of elevated or irritable mood (mania or hypomania) and depressive episodes, with periods of relative stability in between. Managing it requires precision: the medications that treat bipolar depression can trigger mania; the mood stabilizers that prevent mania carry significant side effect burdens; and the anxiety and sleep disruption that accompany bipolar disorder add layers of complexity to an already difficult treatment picture.
It's no surprise that many people with bipolar disorder explore adjunctive options, including CBD oil. This article takes an honest look at what the research shows, what CBD oil genuinely cannot do in bipolar disorder, where it may offer some adjunctive benefit, and — critically — what safety considerations apply given the medications most people with this condition are taking.
Bipolar I vs. Bipolar II: Why the Distinction Matters for CBD
Bipolar disorder is not a single entity. The DSM-5 distinguishes several subtypes, and the distinction between Bipolar I and Bipolar II is clinically significant when considering any adjunctive intervention:
| Feature | Bipolar I | Bipolar II |
|---|---|---|
| Manic episodes | Full mania (≥7 days or hospitalization); can include psychosis | Hypomania only (≥4 days, less severe, no psychosis) |
| Depressive burden | Significant, but manic episodes define the diagnosis | Depression predominates; often misdiagnosed as MDD |
| Antidepressant risk | High — antidepressants can trigger mania or rapid cycling | Moderate — some risk of hypomanic switch |
| Primary pharmacotherapy | Lithium, valproate, atypical antipsychotics | Lamotrigine, lithium, quetiapine; antidepressants with caution |
| CBD consideration | More caution warranted; full mania risk higher | Slightly more flexibility, but mood destabilization risk still applies |
The mania-triggering risk of antidepressant-like compounds is a central concern with any adjunctive intervention in bipolar disorder. While CBD is not classified as an antidepressant, its 5-HT1A partial agonism and BDNF-related neuroplasticity effects overlap mechanistically with antidepressant pathways. Whether these effects are sufficient to trigger a manic switch is not established — but the theoretical risk is real enough that caution is warranted, particularly in Bipolar I.
What CBD Oil Cannot Do in Bipolar Disorder
CBD Is Not a Mood Stabilizer — This Is Non-Negotiable
Mood stabilizers (lithium, valproate, lamotrigine, carbamazepine) work by stabilizing neuronal membrane excitability, modulating intracellular signaling cascades (GSK-3β, inositol pathways), and dampening the kindling effect that underlies episode recurrence. CBD does not do any of these things. It has no evidence of preventing manic episodes, shortening their duration, or reducing cycling frequency. Using CBD oil as a substitute for a prescribed mood stabilizer — even briefly — is not supported by any evidence and carries serious risk of relapse. This article will not suggest otherwise.
CBD also does not treat psychosis associated with mania, does not replace antipsychotic medication used in bipolar management, and does not address the lithium or valproate blood level monitoring required for safe ongoing treatment. These are non-negotiable boundaries.
Where CBD Oil May Offer Adjunctive Support
The Bipolar Depression Phase
People with bipolar disorder spend significantly more time in depressive phases than manic ones — in Bipolar II, depression can account for 50% or more of symptomatic time. The depressive phase of bipolar disorder is notoriously difficult to treat: standard antidepressants carry switch risk, and many patients experience inadequate relief from mood stabilizers alone for depressive symptoms.
This is the area where CBD oil's potential adjunctive role is most plausible. CBD's neuroplasticity and BDNF-supporting effects (the same mechanisms explored in unipolar depression — see our CBD and depression guide) could theoretically support the depressive phase without the antidepressant switch risk of SSRIs. CBD's anti-inflammatory properties via CB2 are also relevant — neuroinflammation is elevated in bipolar disorder, particularly in depressive phases, and inflammatory biomarkers (CRP, IL-6) correlate with episode severity.
However, it must be stated clearly: there are no published randomized controlled trials of CBD specifically for bipolar depression. The mechanistic rationale is interesting; the clinical evidence in this population is essentially absent. Any benefit would be adjunctive to stable mood stabilizer therapy, not a replacement for it.
Anxiety Comorbidity
Anxiety disorders co-occur with bipolar disorder at very high rates — estimates suggest 50–75% of people with bipolar disorder have at least one comorbid anxiety disorder. This is clinically problematic because the standard treatments for anxiety (benzodiazepines, SSRIs) carry their own risks in bipolar disorder: benzos are habit-forming and can worsen depressive phases; SSRIs can trigger switching.
CBD oil's anxiolytic properties — well-documented across multiple anxiety presentations in our anxiety guide, GAD guide, and stress guide — represent a potentially useful option for anxiety management in bipolar disorder precisely because CBD does not appear to carry the antidepressant switch risk of SSRIs (though this has not been formally studied in bipolar populations specifically). This is one of the more frequently cited reasons psychiatrists who discuss CBD with patients mention it in the bipolar context.
Sleep Disruption as a Bipolar Prodrome
Sleep disruption is both a symptom of bipolar episodes and a prodrome — an early warning sign that an episode is approaching. Decreased need for sleep is a hallmark of impending mania; insomnia and hypersomnia are common in bipolar depression. Many people with bipolar disorder and their clinicians monitor sleep quality as a key indicator of mood stability.
Supporting sleep quality during euthymic (stable) periods may help maintain the stability that is the goal of ongoing bipolar treatment. The Nano CBD + CBN + D9 Gummies with Melatonin address multiple aspects of sleep disruption: CBD for pre-sleep anxiety, CBN for sedation, and melatonin for circadian anchoring. Circadian rhythm disruption is particularly relevant in bipolar disorder — social rhythm therapy (a component of IPSRT) specifically targets circadian stability as a mood-stabilizing intervention.
For more on CBD's sleep mechanisms, see our comprehensive sleep guide.
Physical Symptoms and Quality of Life
Many people with bipolar disorder experience chronic physical symptoms between episodes — fatigue, muscle tension, headaches, and GI symptoms — that are not always well-addressed by mood stabilizers. The Nano CBD Muscle and Joint Cream applied topically to areas of tension works through local CB1/CB2 receptors without adding to systemic CBD load, making it a lower-risk option for someone managing complex medication interactions.
The THC Question: Why It Matters Especially in Bipolar Disorder
Cannabis use in bipolar disorder is associated with worsened outcomes — earlier onset, more frequent episodes, greater severity, and worse functional recovery. Critically, this research is primarily about THC, not CBD. THC can destabilize mood in bipolar disorder, increase psychosis risk (particularly relevant in Bipolar I with psychotic features), and interact adversely with mood stabilizers.
CBD is chemically and pharmacologically distinct from THC and does not carry the same risks. In fact, some research suggests CBD may counteract certain adverse effects of THC. However, because the negative cannabis-bipolar associations are well-established and because many studies do not separate CBD from THC, people with bipolar disorder should be particularly careful to use only verified THC-free products. PureCraft's broad-spectrum products are third-party tested to confirm THC-free status — this matters more in the bipolar population than almost any other.
Drug Interactions: The Most Critical Section
Drug interactions are the most practically important aspect of CBD use in bipolar disorder, because the medications used to treat it include some of the highest-risk interaction partners for CBD:
| Medication | Role in Bipolar Tx | CBD Interaction | Risk Level |
|---|---|---|---|
| Lithium | Gold standard mood stabilizer | Lithium is not CYP-metabolized; interaction less direct. However, both affect renal clearance indirectly; dehydration risk if both affect fluid balance. Monitor lithium levels closely. | Moderate — monitor |
| Valproate (Depakote) | Mood stabilizer / anti-manic | HIGH — Epidiolex RCT data shows CBD raises valproate levels and valproate raises CBD levels; liver enzyme elevation (ALT/AST) risk; valproate toxicity is serious | HIGH — requires medical supervision |
| Lamotrigine (Lamictal) | First-line for bipolar depression prevention | Moderate — CBD may affect lamotrigine glucuronidation; altered levels possible; monitor for rash (Stevens-Johnson risk doesn't increase, but level changes matter | Moderate — discuss with prescriber |
| Carbamazepine (Tegretol) | Mood stabilizer; strong CYP inducer | HIGH — carbamazepine is a potent CYP3A4 inducer; may reduce CBD blood levels by 50%+ while CBD affects carbamazepine metabolism in return | HIGH — complex bidirectional |
| Quetiapine (Seroquel) | Atypical antipsychotic; used for mania and bipolar depression | Moderate — CYP3A4; additive sedation risk; monitor | Moderate |
| Benzodiazepines (clonazepam, lorazepam) | Sometimes used short-term for acute agitation | HIGH — CYP3A4; additive CNS depression; avoid unless medically supervised | HIGH |
Valproate Interaction — Requires Blood Level Monitoring
The CBD-valproate interaction is the most clinically significant in this population and is supported by Epidiolex trial data — not just theoretical. Both CBD and valproate inhibit each other's metabolism, leading to elevated levels of both. Valproate toxicity (tremor, confusion, liver damage, thrombocytopenia) is a real risk at elevated levels. If you take valproate and are considering CBD oil, this must be discussed with your prescriber first, and valproate blood levels should be monitored after starting CBD and after any dose change.
Dosing Approach: Conservative and Adjunctive
Given the interaction risks and the mood destabilization concern, if CBD oil is to be explored in bipolar disorder it should be approached more conservatively than in other conditions:
| Principle | Rationale |
|---|---|
| Start at the lowest dose (5–10mg) | Interaction risk means lower doses carry less potential for drug level changes |
| Only during stable (euthymic) periods | Introducing a new variable during an episode makes cause-and-effect impossible to assess |
| Inform your prescriber before starting | Valproate and carbamazepine require blood level monitoring when CBD is added |
| Monitor mood daily for at least 4 weeks | Track for any signs of hypomania (decreased sleep need, elevated energy, racing thoughts) and stop if they appear |
| THC-free products only | THC is associated with episode destabilization; broad-spectrum CBD with verified THC-free testing is the only appropriate choice |
PureCraft's nanoemulsified broad-spectrum products provide a THC-free option with superior bioavailability (50–80% vs. 6–19% for standard oil), meaning smaller doses deliver more consistent plasma levels — an advantage when minimizing dose and monitoring for drug interactions. The Nano CBD Broad Spectrum Oil allows precise dosing at low levels (one partial dropper). For sleep support, the CBD+CBN+Melatonin Gummies provide a fixed-dose format with no titration guesswork. For localized physical tension, the Muscle and Joint Cream adds no systemic CBD load.
Learn more about nanoemulsification and why bioavailability matters for dosing precision.
Frequently Asked Questions
Can CBD oil trigger mania or a hypomanic episode?
This is the most important safety question and the honest answer is: we don't know for certain, but the theoretical risk exists. CBD's 5-HT1A partial agonism and BDNF-related neuroplasticity overlap with antidepressant mechanisms, and antidepressants are known to trigger manic switching in a subset of bipolar patients. Whether CBD's effect is sufficient to trigger a switch has not been formally studied in bipolar populations. The few case reports that exist are mixed. The safest approach is to start at a very low dose during a stable period, monitor mood daily, and stop immediately if early hypomanic signs appear (decreased sleep need, elevated energy, increased goal-directed activity, racing thoughts, unusual confidence). Your prescriber should know you are trying CBD.
Can CBD oil help with bipolar depression specifically?
Bipolar depression is the most plausible target for CBD oil's potential adjunctive benefit — and also the most nuanced. The neuroinflammatory component of bipolar depression (elevated CRP, IL-6, TNF-α during depressive phases) is a legitimate target for CBD's CB2-mediated anti-inflammatory properties. CBD's BDNF-supporting neuroplasticity effects could theoretically help with the hippocampal volume loss seen in bipolar disorder. However, there are zero published RCTs of CBD for bipolar depression as of 2026. Any use would be adjunctive to an established mood-stabilizing regimen, not as a replacement for it, and must be discussed with your psychiatrist given the antidepressant-like mechanism concern.
Is CBD oil safe with lithium?
Lithium does not undergo significant CYP450 metabolism — it is excreted renally — so the major CBD-drug interaction mechanism (CYP inhibition) is less directly applicable. However, lithium has a narrow therapeutic window, and anything that affects hydration, renal clearance, or electrolyte balance can shift lithium levels. CBD's generally mild effects on fluid balance are unlikely to be clinically significant, but regular lithium level monitoring (which should already be happening) is especially important if adding CBD. Report the addition to your prescribing physician so they can track levels at the next scheduled check. The interaction is lower risk than with valproate or carbamazepine, but it is not zero risk.
Is CBD oil safe with valproate (Depakote)?
This interaction is the most important in the bipolar context and requires prescriber involvement. Epidiolex (pharmaceutical CBD) trials in epilepsy documented a bidirectional interaction: CBD raises valproate levels and valproate raises CBD levels, and both together increase liver enzyme elevation risk. These findings from pharmaceutical-dose CBD are relevant even for supplement-dose CBD, especially at higher doses. If you take valproate and want to try CBD oil, the responsible path is: inform your prescriber, get a baseline valproate level and liver function panel, start at the lowest possible dose, and recheck both after 4 weeks. Do not proceed without this monitoring in place.
Can CBD oil help with the anxiety that comes with bipolar disorder?
Anxiety comorbidity is extremely common in bipolar disorder and often undertreated, because benzodiazepines carry dependence and depression risks, and SSRIs carry switch risk. CBD oil's anxiolytic properties — well-documented in generalized anxiety, social anxiety, and stress contexts — represent one of the more reasonable potential adjunctive applications in bipolar disorder, precisely because CBD does not appear to carry the same switching risk as SSRIs (though this has not been formally studied in bipolar populations). The Nano CBD Broad Spectrum Oil taken daily may help manage baseline anxiety between mood episodes without the risks associated with standard anti-anxiety pharmacotherapy in this population.
Does CBD oil affect sleep differently in bipolar disorder?
Sleep is a sentinel sign in bipolar disorder — disruption often precedes episodes and worsens their severity. Supporting sleep quality during euthymic periods is a legitimate therapeutic target. CBD's sleep-supporting properties (anxiolytic for pre-sleep anxiety, possible direct sleep-architecture effects) are relevant here, and the addition of CBN (sedating minor cannabinoid) and melatonin (circadian anchoring) in products like the CBD+CBN+Melatonin Gummies addresses multiple sleep disruption mechanisms. Importantly, CBD does not suppress REM sleep — unlike some sleep aids — which is relevant because REM disruption can worsen mood instability. Melatonin itself has some evidence for mood-stabilizing properties in bipolar disorder, adding another layer of rationale for this combination.
Will CBD oil interact with lamotrigine (Lamictal)?
Lamotrigine is metabolized primarily via glucuronidation (UGT enzymes) rather than CYP450, which means CBD's primary CYP interaction mechanism is less directly applicable. However, some research suggests CBD can affect UGT enzymes, and the combination warrants monitoring. Lamotrigine's therapeutic window is clinically important — too little and mood protection is lost; too much carries side effect risk. If you take lamotrigine and add CBD oil, inform your prescriber. If you notice any changes in lamotrigine side effects (dizziness, double vision, rash) or changes in mood stability, have your lamotrigine level checked. The interaction risk is lower than with valproate or carbamazepine, but monitoring is still prudent.
Is full-spectrum or broad-spectrum CBD oil better for bipolar disorder?
Broad-spectrum CBD oil — which contains multiple cannabinoids and terpenes for entourage effect but is tested to confirm THC-free status — is the only appropriate choice for bipolar disorder. Full-spectrum products contain trace THC, and THC is associated with mood destabilization, increased episode frequency, and psychosis risk in bipolar disorder (particularly Bipolar I). Even trace amounts create unnecessary risk in this population. PureCraft's broad-spectrum line provides the entourage effect benefits of multiple cannabinoids without THC, and all products are third-party tested with certificates of analysis confirming THC-free status.
Can CBD oil help with the cognitive side effects of bipolar medications?
Cognitive side effects — brain fog, memory difficulties, slowed processing — are common complaints among people taking lithium, valproate, and especially quetiapine. CBD's neuroprotective and anti-inflammatory properties provide some theoretical rationale for cognitive support, and some preclinical research suggests CBD may support hippocampal function and neuroplasticity. However, there is essentially no clinical trial data on CBD for medication-induced cognitive side effects in bipolar disorder. Before attributing cognitive symptoms to your medication and exploring supplements, discuss these symptoms with your prescriber — dosage adjustment or medication switching may be more effective, and some cognitive symptoms remit with mood stabilization itself.
How long does CBD oil take to show effects in bipolar disorder?
Because the most plausible application of CBD oil in bipolar disorder is adjunctive support for anxiety, sleep, and potentially depressive-phase symptoms, the timeline follows that of these applications: acute effects on anxiety and sleep onset are noticeable within the first few sessions with nanoemulsified CBD (15–30 minute onset sublingually); broader mood-adjacent effects, if any, require consistent daily use over 4–8 weeks to assess. The practical challenge is that in bipolar disorder, mood naturally cycles, and distinguishing CBD effects from the natural course of the illness requires a longer observation window and ideally a consistent mood-tracking practice (NIMH Life Chart or equivalent) so you can observe trends rather than day-to-day variation.
Related Articles
- CBD Oil for Depression
- CBD Oil for Anxiety: A Complete Guide
- CBD Oil for Sleep
- CBD Oil for Stress
- CBD Oil for Generalized Anxiety Disorder (GAD)
- CBD Oil for PTSD
- CBD and Drug Interactions: What You Need to Know
- CBD Oil for Seasonal Affective Disorder (SAD)
- What Is Nano CBD? Bioavailability Explained
References
- Blessing EM, et al. "Cannabidiol as a Potential Treatment for Anxiety Disorders." Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731.
- Shannon S, et al. "Cannabidiol in Anxiety and Sleep: A Large Case Series." Permanente Journal. 2019;23:18–041. PMID: 30624194.
- Corroon J, Phillips JA. "A Cross-Sectional Study of Cannabidiol Users." Cannabis and Cannabinoid Research. 2018;3(1):152–161. PMID: 30014038.
- Zanelati TV, et al. "Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors." British Journal of Pharmacology. 2010;159(1):122–128. PMID: 20002096.
- Russo EB. "Clinical Endocannabinoid Deficiency Reconsidered." Cannabis and Cannabinoid Research. 2016;1(1):154–165. PMID: 28861491.
- Capano A, et al. "Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients." Postgraduate Medicine. 2020;132(1):56–61. PMID: 31711352.
